The tumour microenvironment presents a major barrier to effective delivery of cancer drugs. Neobe Therapeutics are breaking through this barrier through cutting edge genetic engineering techniques putting them at the forefront of immunotherapy delivery.
Bill Carton
December 4, 2025
Hypoxia — a lack of oxygen — is a cornerstone of many tumours which vastly impairs the effectiveness of cancer therapies. StimOxyGen are breathing life back into cancer treatment with their proprietary technology designed to inject oxygen into tumours, massively increasing the effectiveness of various therapies.
Lucy Ahern
November 6, 2025
GitLife Biotech tackles a key challenge in synthetic biology: proving ownership and tracking provenance of engineered biological assets. Their tools replace outdated methods like lab notebooks and unlock commercial potential for labs and start-ups. They envision widespread adoption — with plans to expand from microorganisms into plants, algae, and mammalian cells.
Lucy Ahern
August 7, 2025
.jpg)
Animal studies have been a pre-requisite for drug discovery since the beginning of clinical trials, but with advances in synthetic biology, is animal testing becoming obsolete in today's drug discovery process? PeptiMatrix are at the forefront of this innovation with their advanced, customisable hydrogel technology, they are poised to take advantage of the drug discovery revolution!
Ariyana Rayatt
May 9, 2025
Jetbio, founded by Professor Kenny Dalgarno and CEO Dennis Camilleri, is developing a 3D bioprinting system called Reactive Jet Impingement (ReJI). ReJI combines drop-on-demand printing with high cell density deposition, enabling precise, clog-free bioprinting of complex tissue models. The technology enhances drug discovery, disease modelling, and regenerative medicine, focusing on osteoarthritis, leukaemia, skin diseases, liver cancer, and cardiotoxicology. Jetbio holds patents for ReJI in the US and Europe, strengthening its market position.
Suruchi Sethi
March 25, 2025
Medusa Pharmaceuticals, founded in 2021 by Dr. James Duboff and Professor Peter Sarkies, has developed a groundbreaking approach to combat antibiotic resistance by combining alkylating agents with aminoglycoside antibiotics to restore their efficacy. Focused on conditions like cystic fibrosis, their method could reduce drug toxicity and address antimicrobial resistance, with promising early results and plans for further development...
Megan Thomas
January 17, 2025
Sign up for our monthly newsletter of upcoming events, recently published insights and SEC updates.
